CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
PF06263276 +5 moredrug
Likely dose
2%Tofacitinib Ointmentfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02193815
NCT02193815Phase 1Completed
CompareCT.gov

A Phase 1, Single- Center, Randomized, Double-blind, Vehicle And Active Comparator-controlled Trial To Evaluate The Antipsoriatic Activity And Safety Of A Topically Applied Pf-06263276 Formulation In A Psoriasis Plaque Test

Pfizer·interventional·Posted Jul 18, 2014·Updated Jun 9, 2016

In Brief

A Phase 1 clinical trial evaluating PF06263276, Vehicle, and 3 other interventions for Psoriasis Vulgaris. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with psoriasis vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 18, 2014
Enrollment StartSep 1, 2014
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.0 years ago

Interventions

PF06263276drug

4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD

Vehicleother

Active ingredient-free vehicle to 4% solution

2%Tofacitinib Ointmentdrug

Daily Dosage: approximately 4 mg tofacitinib

Vehicleother

Active ingredient-free vehicle to 2% Ointment

Daivonexdrug

Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg

Daivonex Ointmentdrug

Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg